Changes of Nicotinamide Phosphoribosyltransferase Expressions in Thyroid Glands of Patients with Different Thyroid Pathologies
Table 1
Characteristics of study groups and results of qPCR reactions.
GD ()
GO ()
TNG ()
Controls ()
Thyroid cancers ()
Age years
43 (38–55.25)
39 (30.5–47)
51.5 (44–59)
54 (44.25–56.75)
56.5 (40–65)
0.0029
Sex F, females; M, males
F 19 (90%) M 2 (10%)
F 19 (95%) M 1 (5%)
F 24 (85.7%) M 4 (14.3%)
F 30 (77%) M 9 (23%)
F 24 (60%) M 16 (40%)
0.001
BMI kg/m2
23 (21.9–25.1)
22.5 (20.7–24.6)
23.45 (21.2–26.3)
23.3 (20.9–26.8)
25.16 (21.2–27.5)
0.7569
Cp HPRT
26.08 (25–27.26)
25.78 (25–26.6)
25.25 (24.60–26.36)
24.56 (24.11–25.99)
26.57 (25.57–29.68)
—
Cp NAMPT
27.65 (26.95–29.4)
25.2 (25.27–27.23)
26.94 (26.21–27.61)
24.40 (23.34–26.22)
28.36 (26.8–30.78)
—
Cr-relative NAMPT expression
0.002 (0.001–0.0025)
0.006 (0.0055–0.0086)
0.003 (0.0019–0.007)
0.006 (0.0025–0.01)
0.0016 (0.00087–0.0026)
<0.000001
Data are expressed in medians and interquartile ranges (IQR) provided in brackets; values followed by the same letters differed significantly. GD: Graves’ disease; GO: Graves’ orbitopathy; TNG: toxic nodular goiter; Cp: crossing point; Cr: concentration ratio.
